country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Referencia número: HY-155108

Copy Link Print Information

OATD-02

Name: OATD-02
Brand: MedChemExpress
SKU: HY-155108
Availability: PreOrder

(Synonyms: OAT-1746)

1 Cited Publications

Revisión del cliente

Based on 1 publication(s) in Google Scholar

OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC₅₀s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS: 2146132-73-0
Fòrmula: C₁₂H₂₅BN₂O₄
Peso molecular:272.15

Almacenamiento:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (285 KB)

OATD-02 Chemical Structure

No. CAS: 2146132-73-0

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (1)
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), 28 nM (rARG1)

In Vitro

OATD-02 inhibits mouse ARG in BMDM cells with IC₅₀ values of 912.9 nM and human ARG2 in transfected CHO-K1 cells with IC₅₀ of 171.6 nM, and inhibits hARG1 in human primary hepatocytes at a much higher micromolar concentration (IC₅₀ = 13 μM) ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

OATD-02 (10 mg/kg, oral gavage) generates a strong and a long pharmacodynamic effect in vivo, and has oral bioavailability of 13%, 30%, and 61% from mouse through rat to dog, respectively^[1].
OATD-02 (5 mg/kg, oral gavage) increases fourfold of the L-arginine concentration in plasma sustained even 1 week after end of a treatment^[1].
OATD-02 (twice per day at 50 mg/kg, oral gavage) inhibits the tumor growth in B16F10 orthotopic xenograft tumor model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

B16F10 orthotopic xenograft tumor model^[1]
Dosage:

Twice per day at 50 mg/kg for 15days
Administration:

Oral gavage
Result:

Inhibited tumor growth (TGI 46%).

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Chemical Information

No. CAS 2146132-73-0
Peso molecular 272.15
Fòrmula C₁₂H₂₅BN₂O₄
SMILES

N[C@]1(C(O)=O)C[C@H](CCB(O)O)CC[C@H]1CN(C)C
Synonyms

OAT-1746
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (1)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti-TGF-β/PD-L1 Bispecific Antibody. [Abstract]

2024 Nov;11(43):e2408598. PMID: 39303165

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (285 KB)
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Borek B, et al. Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy. Mol Cancer Ther. 2023;22(7):807-817. [Content Brief]

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

OATD-02

1 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Obtener un presupuesto En stock

Other size

Obtener un presupuesto

Amount: USD 0.00

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (1)
Pureza y Documentación
Referencias

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

OATD-02

Publications Citing Use of MedChemExpress (MCE) OATD-02